Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease | Pediatric Rheumatology | Full Text
Treatment Options for Refractory Kawasaki Disease
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
Role of IVIG in Kawasaki Disease – Pediatric Practice… Pearls for your Pediatric Office Practice
Kawasaki Dis Canada on X: "Approximately 10% to 20% of patients with Kawasaki disease develop recrudescent or persistent fever at least 36 hours after the end of their IVIG infusion and are
Anemia in Kawasaki disease | Encyclopedia MDPI
Kortikosteroide verbessern das Outcome beim Kawasaki-Syndrom - Biermann Medizin
The Role of Neutrophil Activation in the Pathogenesis of Kawasaki Disease | Insight Medical Publishing
Diagnostics | Free Full-Text | Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
Prediction Models for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Meta-analysis - Cardiology - Pediatrics Video Abstracts
Treat acute Kawasaki disease with aspirin plus intravenous immunoglobulin to improve coronary outcomes | SpringerLink
Frontiers | Kawasaki Disease
Flow chart of the study. IVIG, intravenous immunoglobulin; KD, Kawasaki... | Download Scientific Diagram
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - The Lancet Child & Adolescent Health
IJMS | Free Full-Text | Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Molecular and immunological biomarkers to predict IVIg response: Trends in Molecular Medicine
Intravenous Immunoglobulin for the Treatment of Kawasaki Disease | Pediatric Annals
JCI - Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C
Clinical characteristics in Kawasaki disease related to intravenous... | Download Table
Predicting immunoglobulin resistance in Kawasaki disease: an assessment of neutrophil to lymphocyte platelet ratio | Italian Journal of Pediatrics | Full Text
The latest scoring systems evaluating non-responsiveness to treatment... | Download Scientific Diagram
Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study - The Lancet Child & Adolescent Health
Kawasaki Kids on X: "Day 4 of Kawasaki Disease Awareness Month IVIG Treatment for Kawasaki Disease is the most widely used treatment to stop the fever and inflammation in the child's body.
Nurse hold human immunoglobulin vial generic drug to treat Sars-CoV-2-related Kawasaki disease Stock Photo by felipecaparros
The Lancet - Kawasaki disease is a self-limited vasculitis that is the most common cause of acquired heart disease in children in developed countries. Although intravenous immunoglobulin (IVIG) is effective therapy, 10–20%
Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease | Semantic Scholar
